15.54 USD
-0.29 (-1.83%)
15.41 USD
-0.13 (-0.84%)
We assign a fundamental rating of 5 out of 10 to GLUE. GLUE was compared to 531 industry peers in the Biotechnology industry. GLUE is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. GLUE has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year GLUE was profitable.
In the past year GLUE had a positive cash flow from operations.
In the past 5 years GLUE always reported negative net income.
GLUE had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
GLUE has a better Return On Assets (4.56%) than 90.74% of its industry peers.
The Return On Equity of GLUE (8.52%) is better than 91.87% of its industry peers.
GLUE has a better Return On Invested Capital (1.69%) than 89.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.56% | ||
| ROE | 8.52% | ||
| ROIC | 1.69% |
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GLUE's Profit Margin of 11.54% is amongst the best of the industry. GLUE outperforms 91.49% of its industry peers.
GLUE's Operating Margin of 4.69% is amongst the best of the industry. GLUE outperforms 89.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.69% | ||
| PM (TTM) | 11.54% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GLUE has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
GLUE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, GLUE has more shares outstanding
GLUE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
GLUE has an Altman-Z score of 2.92. This is not the best score and indicates that GLUE is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.92, GLUE is in the better half of the industry, outperforming 68.43% of the companies in the same industry.
There is no outstanding debt for GLUE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 2.92 |
ROIC/WACC0.19
WACC8.8%
2.3 Liquidity
A Current Ratio of 6.54 indicates that GLUE has no problem at all paying its short term obligations.
With a decent Current ratio value of 6.54, GLUE is doing good in the industry, outperforming 66.73% of the companies in the same industry.
A Quick Ratio of 6.54 indicates that GLUE has no problem at all paying its short term obligations.
The Quick ratio of GLUE (6.54) is better than 67.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.54 | ||
| Quick Ratio | 6.54 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 116.94% over the past year.
GLUE shows a strong growth in Revenue. In the last year, the Revenue has grown by 1112.27%.
EPS 1Y (TTM)116.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.79%
Revenue 1Y (TTM)1112.27%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%38.54%
3.2 Future
GLUE is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -8.93% yearly.
The Revenue is expected to grow by 22.64% on average over the next years. This is a very strong growth
EPS Next Y71.45%
EPS Next 2Y-22.42%
EPS Next 3Y-13.55%
EPS Next 5Y-8.93%
Revenue Next Year424.57%
Revenue Next 2Y41.6%
Revenue Next 3Y36.35%
Revenue Next 5Y22.64%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 50.13, GLUE can be considered very expensive at the moment.
90.74% of the companies in the same industry are more expensive than GLUE, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.38, GLUE is valued quite expensively.
The Forward Price/Earnings Ratio is negative for GLUE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 50.13 | ||
| Fwd PE | N/A |
4.2 Price Multiples
GLUE's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. GLUE is cheaper than 93.01% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of GLUE indicates a rather cheap valuation: GLUE is cheaper than 99.05% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.98 | ||
| EV/EBITDA | 27.12 |
4.3 Compensation for Growth
GLUE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A cheap valuation may be justified as GLUE's earnings are expected to decrease with -13.55% in the coming years.
PEG (NY)0.7
PEG (5Y)N/A
EPS Next 2Y-22.42%
EPS Next 3Y-13.55%
5. Dividend
5.1 Amount
GLUE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
15.54
-0.29 (-1.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.52%
Inst Owner Change7.39%
Ins Owners0.81%
Ins Owner Change0%
Market Cap1.01B
Revenue(TTM)181.54M
Net Income(TTM)20.95M
Analysts84
Price Target17.78 (14.41%)
Short Float %10.85%
Short Ratio6.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.53%
Min EPS beat(2)13.2%
Max EPS beat(2)61.87%
EPS beat(4)4
Avg EPS beat(4)354.59%
Min EPS beat(4)13.2%
Max EPS beat(4)1080.39%
EPS beat(8)7
Avg EPS beat(8)177.66%
EPS beat(12)11
Avg EPS beat(12)119.51%
EPS beat(16)13
Avg EPS beat(16)84.82%
Revenue beat(2)2
Avg Revenue beat(2)120.76%
Min Revenue beat(2)110.55%
Max Revenue beat(2)130.97%
Revenue beat(4)4
Avg Revenue beat(4)277.19%
Min Revenue beat(4)110.55%
Max Revenue beat(4)444.91%
Revenue beat(8)6
Avg Revenue beat(8)183.66%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.27%
PT rev (3m)7.02%
EPS NQ rev (1m)-2.65%
EPS NQ rev (3m)-37.58%
EPS NY rev (1m)10.67%
EPS NY rev (3m)-34.31%
Revenue NQ rev (1m)0.93%
Revenue NQ rev (3m)-16.26%
Revenue NY rev (1m)8.74%
Revenue NY rev (3m)-1.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 50.13 | ||
| Fwd PE | N/A | ||
| P/S | 5.57 | ||
| P/FCF | 6.98 | ||
| P/OCF | 6.79 | ||
| P/B | 4.12 | ||
| P/tB | 4.12 | ||
| EV/EBITDA | 27.12 |
EPS(TTM)0.31
EY1.99%
EPS(NY)-1.53
Fwd EYN/A
FCF(TTM)2.23
FCFY14.33%
OCF(TTM)2.29
OCFY14.74%
SpS2.79
BVpS3.78
TBVpS3.78
PEG (NY)0.7
PEG (5Y)N/A
Graham Number5.13
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.56% | ||
| ROE | 8.52% | ||
| ROCE | 2.14% | ||
| ROIC | 1.69% | ||
| ROICexc | 94.17% | ||
| ROICexgc | 94.17% | ||
| OM | 4.69% | ||
| PM (TTM) | 11.54% | ||
| GM | N/A | ||
| FCFM | 79.89% |
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 49.42% | ||
| Cap/Sales | 2.27% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 885.62% | ||
| Profit Quality | 692.36% | ||
| Current Ratio | 6.54 | ||
| Quick Ratio | 6.54 | ||
| Altman-Z | 2.92 |
F-Score8
WACC8.8%
ROIC/WACC0.19
Cap/Depr(3y)233.13%
Cap/Depr(5y)356.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)116.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.79%
EPS Next Y71.45%
EPS Next 2Y-22.42%
EPS Next 3Y-13.55%
EPS Next 5Y-8.93%
Revenue 1Y (TTM)1112.27%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%38.54%
Revenue Next Year424.57%
Revenue Next 2Y41.6%
Revenue Next 3Y36.35%
Revenue Next 5Y22.64%
EBIT growth 1Y106.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.16%
EBIT Next 3Y42.19%
EBIT Next 5YN/A
FCF growth 1Y218.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y253.12%
OCF growth 3YN/A
OCF growth 5YN/A
MONTE ROSA THERAPEUTICS INC / GLUE FAQ
Can you provide the ChartMill fundamental rating for MONTE ROSA THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 5 / 10 to GLUE.
Can you provide the valuation status for MONTE ROSA THERAPEUTICS INC?
ChartMill assigns a valuation rating of 4 / 10 to MONTE ROSA THERAPEUTICS INC (GLUE). This can be considered as Fairly Valued.
What is the profitability of GLUE stock?
MONTE ROSA THERAPEUTICS INC (GLUE) has a profitability rating of 4 / 10.
What is the earnings growth outlook for MONTE ROSA THERAPEUTICS INC?
The Earnings per Share (EPS) of MONTE ROSA THERAPEUTICS INC (GLUE) is expected to grow by 71.45% in the next year.